• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc. - Common Stock (NQ:VOR)

20.10 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vor Biopharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
November 11, 2025
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial ↗
November 11, 2025
Vor Biopharma prices $100 million share offering as partner RemeGen reports strong Phase 3 results for telitacicept in IgA nephropathy. 
Via Benzinga
News headline image
US Stocks Mixed; Sea Shares Gain After Q3 Results ↗
November 11, 2025
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Tuesday's pre-market session. ↗
November 11, 2025
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
November 11, 2025
 
Via Benzinga
News headline image
Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗
November 11, 2025
 
Via Benzinga
News headline image
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
November 10, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
These stocks are moving in today's after hours session ↗
November 10, 2025
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
November 10, 2025
 
Via Benzinga
News headline image
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
November 10, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
November 08, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in Upcoming Investor Conferences
November 07, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
November 03, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
October 29, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
October 22, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
October 17, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗
October 16, 2025
Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026. 
Via Benzinga
News headline image
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
October 16, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears ↗
October 14, 2025
Telitacicept showed strong efficacy and safety in a 48-week Phase 3 trial for Sjögren's disease, meeting all primary and secondary endpoints. 
Via Benzinga
News headline image
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
October 14, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
October 01, 2025
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
September 30, 2025
 
Via Benzinga
News headline image
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
September 29, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
September 23, 2025
Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launches 
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
September 17, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
September 12, 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
September 02, 2025
Experienced legal leader brings deep expertise in governance, strategic transactions, and risk management to support Vor Bio’s growth 
From Vor Biopharma
Via GlobeNewswire
News headline image
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari ↗
August 28, 2025
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap